Tag Archives: Chief Technology Officer

Business, Finance, Occupation & Industry

Provectus Presents Data on PV-10 Combination Therapy at American Association of Cancer Research Annu

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Provectus Presents Data on PV-10 Combination Therapy at American Association of Cancer Research Annual Meeting

KNOXVILLE, Tenn.–(BUSINESS WIRE)– Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, presented data on PV-10 combination therapy today at the American Association for Cancer Research (AACR) Annual Meeting in Washington, DC.

The presentation, based upon Abstract #4755 entitled, “Combination of PV-10 Immuno-chemoablation and Systemic Anti-CTLA-4 Antibody Therapy in Murine Models of Melanoma,” was authored by Eric Wachter, Savannah Blair, Jamie Singer and Craig Dees, all of Provectus Pharmaceuticals. The poster was presented by Dr. Wachter, Chief Technology Officer.

PV-10 is Provectus Pharmaceuticals‘s novel oncology drug designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Previous preclinical and clinical studies have established that upon intralesional (IL) administration, PV-10 localizes to injected tumor tissues while rapidly clearing from healthy tissue. Intralesional injection with PV-10 focuses the ablative impact on injected tumors and minimizes the potential for systemic side effects, making it an attractive candidate for both monotherapy and for combination therapy with other agents.

In Phase 2 testing PV-10 elicited an objective response rate of 51% in melanoma patients (CR: 25%; PR: 26%) after 1-4 treatment cycles, with a third of patients experiencing an objective response in their monitored untreated tumors (CR: 26%; PR: 7% in 42 patients with monitored untreated lesions). This apparent immune-mediated bystander response was highly correlated with successful ablation of injected tumors. Recent mechanism studies in B16 murine melanoma tumor lines have confirmed that PV-10 ablation induces T-cell mediated tumor-specific immunity, resulting in marked suppression of untreated metastases and tumor-specific IFN-ˠ production.

The data presented today at AACR utilized systemic immune stimulation by the anti-CTLA-4 antibody 9H10 to explore the potential benefit of combination therapy with PV-10 immuno-chemoablation in murine melanoma. Because advanced melanoma patients, particularly those with stage IV disease, have substantial tumor burden in areas that are often non-accessible to injection with PV-10, combination of PV-10 with systemic therapy may afford advantage in control of uninjected disease while the immunologic effects of PV-10 reach full potential. By combining PV-10 with the anti-CTLA-4 antibody 9H10 in very aggressive murine models of metastatic disease, researchers at Provectus aimed to ensure that any systemic treatment was potentially safe in combination with PV-10, and that efficacy signals from the combination therapy could be differentiated from those of PV-10 alone.

In order to discriminate the systemic effect of PV-10 alone from that in

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Lumesis Names Vincent Aubrun CTO & VP of Engineering

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Lumesis Names Vincent Aubrun CTO & VP of Engineering


Addition of Veteran Technology Professional to Executive Team and Expansion of Sales & Marketing Supports Accelerating Growth

STAMFORD, Conn.–(BUSINESS WIRE)– Lumesis, a Software-as-a-Service (SaaS), cloud-based financial services technology firm for the Municipal Fixed Income Marketplace, today announced the appointment of Vincent Aubrun as Chief Technology Officer and VP of Engineering. In this newly created position, Aubrun will lead all technology initiatives at Lumesis to deliver increasingly powerful and comprehensive software solutions tailored to meet the unique needs of its clients. In addition, Lumesis has significantly increased its Sales & Marketing team as the firm’s growth accelerates.

“The expansion of our Executive Team to include someone with Vincent’s knowledge and skills highlights the success of our DIVER platform and our vision for the future,” said Tim Stevens, co-founder and President at Lumesis. “Vincent’s rich experience will add to our ability to provide innovative solutions to the asset managers, insurance companies, banks, mutual funds, broker dealers and other buy and sell-side institutions that we serve. Vincent brings more than 25 years of expertise in leading application and infrastructure architecture, software development, and systems integration of open source and proprietary technologies. His experience is ideal to help drive our growth strategy and platform development efforts. As Lumesis continues to enhance and expand our product offerings and increase our client base, it is critical to have the right expertise and leadership in place to drive our technology forward.”

“I am excited to join Lumesis in this phase of the company’s growth and evolution,” said Aubrun. “Lumesis presents an incredible opportunity for the muni-bond marketplace, bringing together a vast amount of data and multiple tools to create a powerful and scalable platform. This set of solutions dramatically improves the analysis and communication of risks and opportunities for everyone in the market. I look forward to building on Lumesis’ success by leveraging leading-edge developments in software technology and seamlessly integrating our solutions with those of our clients.”

Prior to joining Lumesis, Aubrun was the CTO of Calypso Technology where he led the transformation of the core product technology and architecture leveraging Open Source solutions to deliver scalability, multi-tenancy and Web interface. He also created a SaaS offering based on the Calypso product. As CTO of Misys Treasury and Capital Markets, Aubrun set technology and architecture strategy for

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

SEMATECH and Intermolecular Partner to Accelerate EUV Lithography and Advanced Transistor Developmen

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

SEMATECH and Intermolecular Partner to Accelerate EUV Lithography and Advanced Transistor Development

Partnership combines strengths to advance critical lithography technology and to accelerate innovation in the continued scaling of logic applications

ALBANY, N.Y. & SAN JOSE, Calif.–(BUSINESS WIRE)– In an effort that will accelerate commercialization of extreme ultraviolet (EUV) lithography technology and the development of next-generation transistors, SEMATECH announced today that Intermolecular, Inc. (NAS: IMI) has joined SEMATECH‘s Lithography and Front End Processes (FEP) programs. The companies have agreed to co-develop new methods to reduce overall cost of ownership (CoO) for Extreme UltraViolet (EUV) lithography, and to co-explore new materials, processes, and integration schemes for advanced logic integrated circuit technologies.

“There are technology gaps the industry needs to address to enable cost-effective insertion of EUV lithography at the 22 nm half-pitch,” said Stefan Wurm, SEMATECH‘s director of Lithography. “SEMATECH is pleased to welcome Intermolecular as a partner. We will work together to accelerate the investigation and qualification of chemical formulations needed to establish a production-worthy EUV lithography technology.”

Intermolecular’s High Productivity Combinatorial (HPC™) platform provides disruptive research and development (R&D) capability that allows for prototyping and characterization of atomic-scale devices at rates 10-100 times faster than can be achieved with conventional approaches. Such methodologies and technologies will be used in both of the program collaborations.

“As semiconductor dimensions are scaled down further, contact resistance remains a critical issue,” said Tony Chiang, Chief Technology Officer, Intermolecular. “Our unique capabilities to accelerate R&D across leading-edge semiconductor processes and devices complement SEMATECH‘s expertise in advanced CMOS test structures and process flows. We are pleased to join in this pre-competitive collaboration intended to accelerate the transfer of new technologies into industry.”

Intermolecular’s mission is to improve R&D efficiency in the semiconductor and clean energy industries through collaborations that use its HPC platform.

About Intermolecular, Inc.

Intermolecular® has pioneered a proprietary approach to accelerate research and development, innovation, and time-to-market for the semiconductor and clean energy industries. The approach consists of its proprietary High Productivity Combinatorial (HPC™) platform, coupled with its multi-disciplinary team. Through paid Collaborative Development Programs (CDPs) with its customers, Intermolecular develops proprietary technology and intellectual property for its customers focused on advanced materials, processes, integration and device architectures. Founded in 2004, Intermolecular is based in San Jose, California. …read more

Source: FULL ARTICLE at DailyFinance